Approximately 20% of these patients present with brain metastases (BMs). Surgical resection, stereotactic radiosurgery, and whole-brain radiation therapy have historically been the primary treatment modalities for patients with non–small-cell lung cancer (NSCLC) and BMs. The treatments for BMs have become complex with the discovery of targetable molecular drivers and the development of an astonishing number of tyrosine kinase inhibitors.The role of immunotherapy in patients with BMs is the subject of ongoing investigations. This article will review the current data and our approach to patients with NSCLC and BMs.
Lung cancer remains the leading cause of cancer-related mortality in the United States. Unfortunately, approximately 57% of patients with non–small-cell lung cancer (NSCLC) present with metastatic disease, and 20% present with brain metastases (BMs) at the time of diagnosis. During the course of the disease, approximately 25% to 50% of patients will develop BMs. The treatments for BMs have become more convoluted, especially in those patients with molecular drivers such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and, c-ros oncogene 1 (ROS1).
The management of Brain Metastases is very much a concerning issue. If we go according to the data given in our article then things can improve.
Reference Link:- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098835/
